MedicalResearch.com Interview with: [caption id="attachment_66392" align="alignleft" width="200"] Prof. Chaturvedi[/caption] Prof. Vishnu Chaturvedi, Ph.D., HCLD Department of Pathology, Microbiology and Immunology New York Medical College Department of Pathology, Westchester Medical Center Valhalla, New York, MedicalResearch.com: What is the background for this study? How does Candida auris differ from Candida albicans, ie in clinical presentation or treatment?    

1. Candida aurisis a newly discovered yeast that is considered a global health threat by the CDC and WHO. The sudden emergence and rapid spread of this multidrug-resistant pathogen is being explained by several published hypotheses. These include global warming, salt water tolerance, or agriculture use of fungicides as plausible causes. In the US, the NY-NJ metropolitan area was the first to suffer from drug-resistant Candia auris clade I genotype. None of the earlier hypotheses could explain the appearance in NY-NJ. Here, we set out to answer two related questions: “why NY-NJ?” and “why clade I?”
2. Candida albicansis a well-known commensal yeast that frequents human mucosal surfaces in the mouth, vagina, etc. In contrast, Candida auris is a newly discovered yeast that colonizes the skin of hospitalized patients and long-term care residents. A small subset of those colonized develop Candida auris bloodstream and deep tissue infections.
3. Candida auris differs from  albicans in its ability to cause healthcare-associated infection outbreaks. Candida auris is also prone to rapid acquisition of the resistance of multiple antifungal drugs. Finally, C. auris bloodstream infections cause high mortality.